Spots Global Cancer Trial Database for pi3k
Every month we try and update this database with for pi3k cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors | NCT00975182 | Non-Squamous No... | GDC-0941 erlotinib HCl | 18 Years - | Genentech, Inc. | |
| Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients | NCT00877773 | Advanced Cancer... | Temsirolimus | - | M.D. Anderson Cancer Center | |
| Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients | NCT00877773 | Advanced Cancer... | Temsirolimus | - | M.D. Anderson Cancer Center | |
| A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | NCT01539512 | Chronic Lymphoc... | Idelalisib Rituximab Placebo to matc... | 18 Years - | Gilead Sciences | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | NCT04208178 | Advanced HER2+B... | Alpelisib Alpelisib match... Trastuzumab Pertuzumab | 18 Years - | Novartis | |
| Study of PX-866 and Docetaxel in Solid Tumors | NCT01204099 | Non Small Cell ... Squamous Cell C... | Docetaxel PX-866 | 18 Years - | Seagen Inc. | |
| Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) | NCT02761694 | Cancer Solid Tumors | Vevorisertib Fulvestrant Paclitaxel | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | NCT01569295 | Chronic Lymphoc... | Idelalisib Rituximab Bendamustine Placebo to matc... | 18 Years - | Gilead Sciences | |
| Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma | NCT01393106 | Hodgkin Lymphom... | Idelalisib | 12 Years - | Gilead Sciences | |
| First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | NCT06239467 | Advanced Cancer Breast Cancer | OKI-219 Fulvestrant Trastuzumab | 18 Years - | OnKure, Inc. | |
| A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi | NCT01633060 | Metastatic Brea... | Fulvestrant BKM120 BKM120 matching... | 18 Years - | Novartis | |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | NCT01282424 | Follicular Lymp... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00996892 | Solid Tumors | Cobimetinib Pictilisib | 18 Years - | Genentech, Inc. | |
| A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors | NCT00907205 | Advanced or Met... Cancer Solid Cancers | SF1126 | 18 Years - | Semafore Pharmaceuticals | |
| A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | NCT00876122 | Non-Hodgkin's L... | GDC-0941 | 18 Years - | Genentech, Inc. | |
| A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors | NCT01195376 | Advanced Solid ... | BEZ235 | 20 Years - | Novartis | |
| A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | NCT00876122 | Non-Hodgkin's L... | GDC-0941 | 18 Years - | Genentech, Inc. | |
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings | NCT01700582 | Carcinoma, Non-... ALK Gene Mutati... KRAS Gene Mutat... BRAF Gene Mutat... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma | NCT01512251 | BRAF Mutant Met... | BKM120 Combined... | 18 Years - | University of California, San Francisco | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma | NCT01393106 | Hodgkin Lymphom... | Idelalisib | 12 Years - | Gilead Sciences | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | NCT03795610 | Head and Neck S... Head and Neck C... Head and Neck C... Head and Neck C... Head and Neck C... HPV-Related Car... HPV-Related Mal... HPV-Related Squ... | IPI-549 | 18 Years - | University of California, San Diego | |
| Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma | NCT03961698 | Breast Cancer Renal Cell Carc... | IPI-549 (eganel... Atezolizumab nab-paclitaxel Bevacizumab | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer | NCT01038037 | Non Small Cell ... | Carboplatin Vinorelbine panitumumab | 18 Years - | Vejle Hospital | |
| First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | NCT06239467 | Advanced Cancer Breast Cancer | OKI-219 Fulvestrant Trastuzumab | 18 Years - | OnKure, Inc. | |
| Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan | NCT00742105 | Cancer Solid Tumor Advanced Solid ... | BGT226 | 20 Years - | Novartis | |
| Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | NCT01569295 | Chronic Lymphoc... | Idelalisib Rituximab Bendamustine Placebo to matc... | 18 Years - | Gilead Sciences | |
| A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | NCT00876109 | Solid Cancers | GDC-0941 | 18 Years - | Genentech, Inc. | |
| Phase 1 and 2 Study of PX-866 and Cetuximab | NCT01252628 | Incurable Metas... Incurable Progr... | PX-866 (SCCHN) Cetuximab (SCCH... PX-866 (CRC) Cetuximab (CRC) | 18 Years - | Seagen Inc. | |
| Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | NCT04997902 | HNSCC | Tipifarnib Alpelisib | 18 Years - | Kura Oncology, Inc. | |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | NCT04485559 | Recurrent World... Low-grade Gliom... High Grade Glio... | Everolimus Trametinib | 1 Year - 25 Years | University of California, San Francisco | |
| Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer | NCT01297491 | Non-small Cell ... | BKM120 | 18 Years - | Novartis | |
| Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan | NCT00742105 | Cancer Solid Tumor Advanced Solid ... | BGT226 | 20 Years - | Novartis | |
| Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor | NCT01610284 | Breast Cancer | Fulvestrant BKM120 BKM120 matching... | 18 Years - | Novartis | |
| Study of PX-866 and Docetaxel in Solid Tumors | NCT01204099 | Non Small Cell ... Squamous Cell C... | Docetaxel PX-866 | 18 Years - | Seagen Inc. | |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | NCT06190899 | mCRPC (Metastat... Genital Disease... Urogenital Dise... Prostatic Disea... Prostatic Neopl... Prostate Cancer | Gedatolisib Darolutamide | 18 Years - | Celcuity Inc | |
| Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer | NCT01347866 | Advanced Cancer | PF-05212384 PD-0325901 PF-05212384 irinotecan | 18 Years - | Pfizer | |
| Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00996892 | Solid Tumors | Cobimetinib Pictilisib | 18 Years - | Genentech, Inc. | |
| Phase 1 and 2 Study of PX-866 and Cetuximab | NCT01252628 | Incurable Metas... Incurable Progr... | PX-866 (SCCHN) Cetuximab (SCCH... PX-866 (CRC) Cetuximab (CRC) | 18 Years - | Seagen Inc. | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Phase I Trial of Oral PX-866 | NCT00726583 | Advanced Solid ... | PX-866 | 18 Years - | Seagen Inc. | |
| A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation | NCT01572727 | Breast Cancer | Paclitaxel BKM120 matching... BKM120 | 18 Years - | Novartis | |
| Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL | NCT05239910 | Peripheral T Ce... | Tenalisib | 18 Years - | Rhizen Pharmaceuticals SA | |
| A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer | NCT00960960 | Breast Cancer | Bevacizumab Pictilisib Letrozole Paclitaxel Trastuzumab | 18 Years - | Genentech, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
